Scandinavian ChemoTech strengthens its working capital
ChemoTech has today signed loan agreements that secures finance of four million SEK from shareholders and investors.Through this financing, ChemoTech has increased liquidity, which ensures that the company can complete the CE-marking process for IQwave™, the company's first product based on the patented tumour-specific electroporation technology, and can continue to work on our prioritized markets. The board will continue to establish the long-term financing plan for the company. “We are pleased to see that the long-term interest and trust in ChemoTech, and its potential, from